The information and tools provided on this website do not, and are not intended to, constitute legal or medical advice. All information, content, and materials available on this site are for general informational purposes only. Information on this website may not constitute the most up-to-date medical, legal, or other information. This website contains links to other third-party websites. Such links are only for the convenience of the reader.
Glaser R, York AE, Dimitrakakis C. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). Maturitas. 2011;68:355-361.
Glaser R, Kalantaridou S, Dimitrakakis C. Testosterone Implants in Women: Pharmacological Dosing for a Physiologic effect. Maturitas. 2013;74:179-184.
Testosterone Therapy in Women: Myths and Misconceptions
Glaser RL, York AE, Dimitrakakis C. Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. BMC Cancer. 2019;19:1271.
Glaser RL, York AE. Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy. Int J Pharm Compd. 2019;23:325-339.
Glaser, R. L., York, A. E., and Dimitrakakis, C. 2017. Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications. Menopause. 24, 7, 859-864.
Glaser RL., Dimitrakakis C. Testosterone and breast cancer prevention. Maturitas. 2015;81:104.
Glaser RL, Dimitrakakis C. Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer. Menopause (New York, NY). 2014;21:673.
Glaser RL, York AE, Dimitrakakis C. Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivors. J Clin Oncol. 2014 Sep 10;32(Suppl 2):109.
Glaser R, York A, Dimitrakakis C. Effect of testosterone therapy on the female voice. Climacteric. 2016;19:2;198.
Glaser R, et al. Testosterone pellet implants and migraine headaches: a pilot study. Maturitas. 2012;71:385-388.
Glaser RL, Dimitrakakis C, Messenger AG. Improvement in scalp hair growth in androgen deficient women treated with testosterone: a questionnaire study. British Journal of Dermatology. 2012;166:274-278.
Dimitrakakis C, Zava D, Marinopoulos S, Tsigginou A, Antsaklis A, Glaser R. Low salivary testosterone levels in patients with breast cancer. BMC cancer. 2010;10:547.
Glaser R, Newman M, Parsons M, Zava D, Glaser-Garbrick D. Safety of maternal testosterone therapy during breast feeding. International journal of pharmaceutical compounding. 2009;13:314.
Glaser RL, Zava DT, Wurtzbacher D. Pilot study: absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina. Gynecologic and obstetric investigation. 2008;66:111-118.
Glaser R, Marinopoulos S, Dimitrakakis C. Breast cancer treatment in women over the age of 80: A tailored approach. Maturitas. 2018;110:29-32.
A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Supportive Care in Cancer. 20201-10.
Glaser, R. L., York, A. E., and Dimitrakakis, C. 2018. Abstract #1435/Poster presentation. Reduced incidence of breast cancer with testosterone implant therapy: a 10-year cohort study. 2018 San Antonio Breast Cancer Symposium. 2018, December: P6-13-02.
A randomized, double-blind, placebo-controlled trial of testosterone (T) for aromatase inhibitor-induced arthralgias (AIA) in postmenopausal women: Alliance A221102. 2018 San Antonio Breast Cancer Symposium. 2018, December: P4-16-01
Glaser, R. L. 2017. Poster presentation and abstract. Testosterone, anastrozole and venous thrombosis. Maturitas. 103, 91.
Neacsu, A. V., Glaser, R. L., and Ceausu, I. 2017. Oral presentation and abstract. Critical role of testosterone in both sexes. Maturitas. 100, 189-190.
Glaser R, Dimitrakakis C. 58 BENEFICIAL EFFECTS OF SUBCUTANEOUS TESTOSTERONE THERAPY ON LIPID PROFILES IN WOMEN. Maturitas. 2012;71:S41.
Glaser R, Dimitrakakis C. 14 SUBGROUPS OF PATIENTS TREATED WITH AN AROMATASE INHIBITOR (ANASTROZOLE) DELIVERED SUBCUTANEOUSLY IN COMBINATION WITH TESTOSTERONE. Maturitas. 2012;71:S31.
Glaser R. Subcutaneous testosterone-anastrozole implant therapy in breast cancer survivors. 2010
Glaser R, Wurtzbacher D, Dimitrakakis C. Efficacy of testosterone therapy delivered by pellet implant. Maturitas. 2009;63:S73-S74.
32. Testosterone Implant Therapy in Women With and Without Breast Cancer- Rationale, Experience, Evidence
32. Testosterone Implant Therapy in Women With and Without Breast Cancer- Rationale, Experience, Evidence Supplemental Table
32. Testosterone Implant Therapy in Women With and Without Breast Cancer- Rationale, Experience, Evidence Supplemental Data 1
32. Testosterone Implant Therapy in Women With and Without Breast Cancer- Rationale, Experience, Evidence Supplemental Data 2
32. Testosterone Implant Therapy in Women With and Without Breast Cancer- Rationale, Experience, Evidence Supplemental Data 3